India’s Pharma Pulse: Empowering India’s Healthcare Potential

India’s pharmaceutical sector is strengthening its role as the “Pharmacy of the World,” driven by robust domestic manufacturing—85% locally produced, supported by 10,000+ facilities and 650 USFDA-approved plants. The industry supplies 20% of global generics and 60% of UNICEF vaccines, while expanding rapidly into biologics, branded generics, and OTC products. CRAMS exports are set to rise from USD 18B in 2023 to USD 44B by 2030, powered by a strong talent base and growing AI adoption. India is also poised to capture 20–30% of outsourced API demand as global supply chains diversify, with major investments from international players, reinforcing its competitive edge.